Top Links You Must Click On
From the Wires
Jennerex Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients With Advanced Hepatocellular Carcinoma (HCC)
High-Dose Pexa-Vec Associated With Statistically Significant Improvement in Median Survival Versus Low-Dose Pexa-Vec (14.1 Months vs. 6.7 Months)
By: Marketwired .
Feb. 10, 2013 01:00 PM
SAN FRANCISCO, CA -- (Marketwire) -- 02/10/13 -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced the publication of research demonstrating the ability of its lead product-candidate, Pexa-Vec (JX-594) to significantly prolong survival in advanced hepatocellular carcinoma (HCC) patients in a randomized dose comparison clinical trial. This research, published in Volume 19, Issue 2 of Nature Medicine, showed a statistically significant dose-dependent overall survival benefit with 14.1 months median overall survival for the high-dose group compared to 6.7 months for the low-dose group (p-value = 0.02). This is the first randomized clinical trial of an oncolytic immunotherapy demonstrating significantly prolonged overall survival.
Pexa-Vec is an oncolytic immunotherapy designed to 1) rapidly de-bulk tumors via tumor cell lysis, 2) activate an antivascular effect with rapid tumor vascular knockout, and 3) induce a durable immune response against tumors. Pexa-Vec was engineered from vaccinia, which has been used for decades as a vaccine in healthy individuals. Pexa-Vec has been safely administered to over 200 patients and is currently in Phase 2b clinical development for the treatment of advanced HCC and is also being evaluated in other solid tumors.
"The treatment options for advanced HCC are limited, with few promising agents currently in development. This Nature Medicine publication highlights the unique possibility of a meaningful survival benefit combined with short-term, transient and manageable side effects," said Tony Reid, M.D., Ph.D., professor of Medicine at University of California, San Diego and co-lead author of the paper. "The findings also showed Pexa-Vec's ability to induce anti-tumor immunity and reduce blood flow to tumors which supports Pexa-Vec's multi-pronged approach to attacking cancer."
The data presented in the Nature Medicine publication showed that Pexa-Vec had clear local anti-cancer response at both the low and high doses. Thirty subjects were randomized into the low and high dose groups and received three Pexa-Vec treatments over the course of four weeks. The results demonstrated that Pexa-Vec treatment at both doses resulted in a reduction in tumor size and decreased blood flow in tumors. The data further demonstrates that Pexa-Vec treatment induced an immune response against the tumor, evidenced by antibody-mediated tumor cell toxicity. Pexa-Vec was well-tolerated at both high and low doses with the most frequent adverse events consisting of fever lasting less than 24 hours.
"This Nature Medicine publication validates our clinical data and the scientific rationale for our approach to treating cancer with oncolytic immunotherapy as well as the continued development of Pexa-Vec for the treatment of HCC and other solid tumors," said Laurent Fischer, M.D., president and chief executive officer of Jennerex. "The opportunity to rapidly de-bulk tumors and provide a long-term immune effect is a significant advance in the treatment of HCC. We are currently enrolling patients in multiple mid and late-stage trials with Pexa-Vec with the goal of bringing this groundbreaking therapy to market."
Pexa-Vec Clinical Development Program and SOLVE Platform
Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that Pexa-Vec, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated (over 200 patients treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. Pexa-Vec has had a predictable and manageable safety profile to date which includes flu-like symptoms that resolve in 24 to 48 hours.
Pexa-Vec is the lead product candidate from Jennerex' SOLVE platform, a groundbreaking approach offering new therapeutic options for patients with life-threatening cancers. SOLVE builds on the natural attributes of vaccinia viruses to engineer highly targeted, oncolytic immunotherapies for cancer with minimal side effects.
About Jennerex's Regional Partners for Pexa-Vec
Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and Pexa-Vec (TG6006) having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded three strategic agreements for the development of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers; an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec (TG6006), an oncolytic virus, and with the EORTC for the development of TG4001 to treat HPV induced head and neck cancers. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.
Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.
Lee's Pharmaceutical Holdings Limited is a research-based biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.
Enterprise Open Source Magazine Latest Stories . . .
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week